Gain Therapeutics to Present at the 38th Annual ROTH Conference

Core Insights - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies [3] - The company will participate in the 38th Annual ROTH Conference from March 22-24, 2026, with a fireside chat scheduled for March 23, 2026, at 11:30 a.m. PT [1][2] Company Overview - Gain Therapeutics is leading the discovery and development of allosteric therapies, with its lead drug candidate GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [3] - The company is also exploring GT-02287's potential in treating Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease [3] - Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors [3] Technology and Approach - Gain's unique approach involves discovering novel allosteric small molecule modulators that can restore or disrupt protein function [4] - The company utilizes its advanced Magellan™ platform to accelerate drug discovery and develop disease-modifying treatments for challenging disorders, including neurodegenerative diseases and rare genetic disorders [4]